US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Generate Biomedicines / Equity Capital Markets

<ul>
<li>GENB's 20.9% first-day decline was among 2026's worst IPO debuts, but shares have since recovered sharply and moved above the $16 IPO price.</li>
<li>GB-0895 remains the key value driver, with two global Phase 3 asthma studies advancing across 33 countries.</li>
<li>Generate exited 2Q26 with $457.4 million of cash and expects funding to support its current operating plan into 1H28.</li>
</ul>


GENB's 20.9% first-day decline was among 2026's worst IPO debuts, but shares have since recovered sharply and moved above the $16 IPO price.
GB-0895 remains the key value driver, with two global Phase 3 asthma studies advancing across 33 countries.
Generate exited 2Q26 with $457.4 million of cash and expects funding to support its current operating plan into 1H28.


Generate Biomedicines (GENB): Post 180-Days, From IPO Disaster to a Remarkable Recovery

<ul>
<li>Priced 25M shares at $16; opened at $15 and closed at $12.65, down 20.9% — worst first-day performance of 2026.</li>
<li>Despite being marketed as “well-oversubscribed,” aftermarket trading revealed clear valuation pushback and price sensitivity.</li>
<li>A negative signal for biotech IPO sentiment and a notable setback for Flagship Pioneering’s public-market track record.</li>
</ul>


Priced 25M shares at $16; opened at $15 and closed at $12.65, down 20.9% — worst first-day performance of 2026.
Despite being marketed as “well-oversubscribed,” aftermarket trading revealed clear valuation pushback and price sensitivity.
A negative signal for biotech IPO sentiment and a notable setback for Flagship Pioneering’s public-market track record.


Generate Biomedicines (GENB): Valuation Pushback Hits Flagship-Backed AI Biotech Company

<ul>
<li>AI-Driven generative biology platform aims to accelerate protein drug design, reducing development timelines and cost of proof of concept.</li>
<li>Strategic collaborations with Amgen, Novartis, MD Anderson, and Roswell Park validate platform credibility.</li>
<li>Backed by Flagship and leading institutional and tech investors, with $221.5M cash entering 2026.</li>
</ul>


AI-Driven generative biology platform aims to accelerate protein drug design, reducing development timelines and cost of proof of concept.
Strategic collaborations with Amgen, Novartis, MD Anderson, and Roswell Park validate platform credibility.
Backed by Flagship and leading institutional and tech investors, with $221.5M cash entering 2026.


Generate Biomedicines (GENB): Flagship Backed Programmable Biology Company Drawing IPO Interest

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Bottom-Up

<ul><li>✅ IPO PROPHET RATING: 7.75/10 🏦 Deal Quality &amp; Underwriters: 8.2/10 Generate Biomedicines, a Flagship Pioneering–backed biotechnology company, is preparing to list on the Nasdaq under the ticker GENB.</li><li>The company plans to offer 25 million shares at a price range of $15 to $17 per share, which would generate approximately $400 to $425 million in gross proceeds at the midpoint.</li><li>Its platform integrates machine learning with advanced biological engineering to develop novel protein therapeutics across multiple disease categories.</li></ul>

✅ IPO PROPHET RATING: 7.75/10 🏦 Deal Quality &amp; Underwriters: 8.2/10 Generate Biomedicines, a Flagship Pioneering–backed biotechnology company, is preparing to list on the Nasdaq under the ticker GENB.The company plans to offer 25 million shares at a price range of $15 to $17 per share, which would generate approximately $400 to $425 million in gross proceeds at the midpoint.Its platform integrates machine learning with advanced biological engineering to develop novel protein therapeutics across multiple disease categories.

<ul><li>Generate Biomedicines has set terms for its initial public offering, seeking to raise approximately $400 million by offering 25,000,000 shares at a price range of $15.00 to $17.00 per share ( Generate Biomedicines S-1_A) .</li><li>At the $16.00 midpoint , the company would raise roughly $400 million in gross proceeds and debut with an implied post-IPO market capitalization of approximately $1.6 billion , excluding any underwriters’ option.</li><li>The company plans to list on the Nasdaq under the ticker GENB , with Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor leading the offering.</li></ul>

Generate Biomedicines has set terms for its initial public offering, seeking to raise approximately $400 million by offering 25,000,000 shares at a price range of $15.00 to $17.00 per share ( Generate Biomedicines S-1_A) .At the $16.00 midpoint , the company would raise roughly $400 million in gross proceeds and debut with an implied post-IPO market capitalization of approximately $1.6 billion , excluding any underwriters’ option.The company plans to list on the Nasdaq under the ticker GENB , with Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor leading the offering.

Generate Biomedicines Sets Terms for $400 Million IPO

United States

Generate Biomedicines, Inc. operates as a clinical-stage generative biology company. The Company focuses on machine learning, biological engineering, and AI to generate optimal therapeutics for the impact on human health. Generate Biomedicines serves patients and healthcare professionals worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Generate Biomedicines (GENB US)

Generate Biomedicines (GENB): Post 180-Days, From IPO Disaster to a Remarkable Recovery

Generate Biomedicines staged a powerful recovery, recently trading as high as $22.67 and rewarding investors willing to look beyond the initial IPO...

IPO Boutique

Generate Biomedicines (GENB): Valuation Pushback Hits Flagship-Backed AI Biotech Company

Flagship Pioneering's biotech IPO flops, priced at $16 but closes at $12.65, worst first-day performance of 2026, signaling valuation pushback.

IPO Boutique

Generate Biomedicines (GENB): Flagship Backed Programmable Biology Company Drawing IPO Interest

AI-driven platform accelerates protein drug design, backed by strategic collaborations and significant funding, poised to revolutionize biotech...

IPO Boutique

IPO Rating: Generate Biomedicines, Inc.

✅ IPO PROPHET RATING: 7.75/10 🏦 Deal Quality & Underwriters: 8.2/10 Generate Biomedicines, a Flagship Pioneering–backed biotechnology company,...

IPO Prophet

Generate Biomedicines Sets Terms for $400 Million IPO

Generate Biomedicines has set terms for its initial public offering, seeking to raise approximately $400 million by offering 25,000,000 shares at...

IPO Prophet

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Generate Biomedicines (GENB): Post 180-Days, From IPO Disaster to a Remarkable Recovery

Generate Biomedicines staged a powerful recovery, recently trading as high as $22.67 and rewarding investors willing to look beyond the initial IPO...

IPO Boutique

Generate Biomedicines (GENB): Valuation Pushback Hits Flagship-Backed AI Biotech Company

​Flagship Pioneering's biotech IPO flops, priced at $16 but closes at $12.65, worst first-day performance of 2026, signaling valuation pushback.

IPO Boutique

Generate Biomedicines (GENB): Flagship Backed Programmable Biology Company Drawing IPO Interest

​AI-driven platform accelerates protein drug design, backed by strategic collaborations and significant funding, poised to revolutionize biotech...

IPO Boutique

IPO Rating: Generate Biomedicines, Inc.

✅ IPO PROPHET RATING: 7.75/10 🏦 Deal Quality & Underwriters: 8.2/10 Generate Biomedicines, a Flagship Pioneering–backed biotechnology company,...

IPO Prophet

Generate Biomedicines Sets Terms for $400 Million IPO

Generate Biomedicines has set terms for its initial public offering, seeking to raise approximately $400 million by offering 25,000,000 shares at...

IPO Prophet

Flagship Pioneering's biotech IPO flops, priced at $16 but closes at $12.65, worst first-day performance of 2026, signaling valuation pushback.

AI-driven platform accelerates protein drug design, backed by strategic collaborations and significant funding, poised to revolutionize biotech...